Mechanism of synergy between N-phosphonacetyl-L-aspartate and dipyridamole in a human ovarian carcinoma cell line.

@article{Chan1985MechanismOS,
  title={Mechanism of synergy between N-phosphonacetyl-L-aspartate and dipyridamole in a human ovarian carcinoma cell line.},
  author={Thomas C.-K. Chan and Stephen B. Howell},
  journal={Cancer research},
  year={1985},
  volume={45 8},
  pages={3598-604}
}
Previous results from our laboratory have shown that the nucleoside transport inhibitor dipyridamole (DP) markedly augmented both the in vitro and in vivo activities of the pyrimidine antimetabolite N-phosphonacetyl-L-aspartate (PALA). In a human ovarian carcinoma cell line (2008), DP increased the activity of PALA by 1 to 2 logs in growth rate and clonogenic assays while exhibiting no cytotoxicity of its own. The concentration of DP used (1 microM) in these assays resulted in over 80… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 18 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 47 references

The antagonism of W - phosphonacetyl - L - aspartate ( PALA ) plus dipyridamole ( DP ) toxicity by uridine

  • T. C. K. Chan, S. B. Howell
  • 1984

The antagonism of W-phosphonacetyl-Laspartate (PALA) plus dipyridamole (DP) toxicity

  • T.C.K. Chan, S. B. Howell
  • by uridine. Pharmacologist,
  • 1984
1 Excerpt

Dipyri damole kinetics

  • C. Mahony, K. M. Wolfram, D. M. Cocchetto, T. D. Bjomsson
  • Clin . Pharmacol . Ther .
  • 1982

Similar Papers

Loading similar papers…